OPKO Health (OPK) Stock Forecast, Price Target & Predictions
OPK Stock Forecast
OPKO Health stock forecast is as follows: an average price target of $3.50 (represents a 138.10% upside from OPK’s last price of $1.47) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
OPK Price Target
The average price target for OPKO Health (OPK) is $3.50 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $3.00. This represents a potential 138.10% upside from OPK's last price of $1.47.
OPK Analyst Ratings
According to 10 Wall Street analysts, OPKO Health's rating consensus is 'Buy'. The analyst rating breakdown for OPK stock is 0 'Strong Buy' (0.00%), 5 'Buy' (50.00%), 5 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
OPKO Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | Yi Chen | H.C. Wainwright | $3.00 | $1.70 | 76.99% | 104.08% |
| Dec 15, 2022 | - | H.C. Wainwright | $3.00 | $1.29 | 132.56% | 104.08% |
| Aug 04, 2022 | Edward Tenthoff | Piper Sandler | $4.00 | $2.40 | 66.67% | 172.11% |
The latest OPKO Health stock forecast, released on Sep 17, 2024 by Yi Chen from H.C. Wainwright, set a price target of $3.00, which represents a 76.99% increase from the stock price at the time of the forecast ($1.70), and a 104.08% increase from OPK last price ($1.47).
OPKO Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $3.00 | $3.00 |
| Last Closing Price | $1.47 | $1.47 | $1.47 |
| Upside/Downside | -100.00% | 104.08% | 104.08% |
In the current month, the average price target of OPKO Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OPKO Health's last price of $1.47. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 17, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Sep 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 17, 2024 | New Street | Buy | Buy | Hold |
| Sep 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 01, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jun 29, 2023 | JMP Securities | - | Market Perform | Initialise |
| Jun 29, 2023 | Guggenheim | - | Neutral | Initialise |
| Jun 29, 2023 | Susquehanna | - | Positive | Upgrade |
| Jun 29, 2023 | Piper Sandler | Overweight | Neutral | Upgrade |
| Jun 29, 2023 | UBS | - | Neutral | Downgrade |
OPKO Health's last stock rating was published by Sandler O'Neill on Sep 17, 2024. The company gave OPK a "Buy" rating, the same as its previous rate.
OPKO Health Financial Forecast
OPKO Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $181.88M | $178.59M | $265.42M | $237.60M | $185.40M | $179.74M | $309.89M | $329.22M | $401.33M | $385.81M | $442.41M | $545.16M | $494.67M | $428.06M | $301.21M | $211.47M | $224.34M | $228.77M |
| Avg Forecast | $184.42M | $175.96M | $164.74M | $160.10M | $185.15M | $177.42M | $169.39M | $161.77M | $167.82M | $181.52M | $184.70M | $182.99M | $177.53M | $174.78M | $201.97M | $193.35M | $168.21M | $183.51M | $326.87M | $332.62M | $329.83M | $302.27M | $456.36M | $494.16M | $443.10M | $378.66M | $245.60M | $218.00M | $216.07M | $225.40M |
| High Forecast | $184.42M | $175.96M | $164.74M | $160.10M | $185.15M | $177.42M | $169.39M | $161.77M | $167.82M | $183.31M | $184.70M | $182.99M | $179.18M | $174.78M | $201.97M | $193.35M | $168.21M | $183.51M | $326.87M | $332.62M | $329.83M | $302.27M | $456.36M | $494.16M | $443.10M | $378.66M | $245.60M | $218.00M | $216.07M | $225.40M |
| Low Forecast | $184.42M | $175.96M | $164.74M | $160.10M | $185.15M | $177.42M | $169.39M | $161.77M | $167.82M | $180.10M | $184.70M | $182.99M | $175.90M | $174.78M | $201.97M | $193.35M | $168.21M | $183.51M | $326.87M | $332.62M | $329.83M | $302.27M | $456.36M | $494.16M | $443.10M | $378.66M | $245.60M | $218.00M | $216.07M | $225.40M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.31% | 1.23% | 1.10% | 0.98% | 0.95% | 0.99% | 1.22% | 1.28% | 0.97% | 1.10% | 1.12% | 1.13% | 1.23% | 0.97% | 1.04% | 1.01% |
OPKO Health's average Quarter revenue forecast for Mar 24 based on 4 analysts is $182.99M, with a low forecast of $182.99M, and a high forecast of $182.99M. OPK's average Quarter revenue forecast represents a 0.61% increase compared to the company's last Quarter revenue of $181.88M (Dec 23).
OPKO Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-161.06M | $-64.41M | $13.20M | $-8.90M | $-41.30M | $-98.17M | $-70.77M | $-46.15M | $-42.78M | $54.67M | $14.03M | $57.02M | $71.38M | $47.06M | $67.47M | $-30.41M | $-80.93M | $-30.64M |
| Avg Forecast | $-8.24M | $-7.86M | $-7.36M | $-7.16M | $-8.28M | $-7.93M | $-7.57M | $-7.23M | $-7.50M | $-8.11M | $-8.26M | $-37.29M | $-7.93M | $-7.81M | $-9.03M | $-33.90M | $-7.52M | $-8.20M | $-14.61M | $-30.82M | $-14.74M | $-13.51M | $-20.40M | $57.02M | $-19.80M | $-16.92M | $-10.98M | $-30.41M | $-9.66M | $-10.07M |
| High Forecast | $-8.24M | $-7.86M | $-7.36M | $-7.16M | $-8.28M | $-7.93M | $-7.57M | $-7.23M | $-7.50M | $-8.05M | $-8.26M | $-29.83M | $-7.86M | $-7.81M | $-9.03M | $-27.12M | $-7.52M | $-8.20M | $-14.61M | $-24.65M | $-14.74M | $-13.51M | $-20.40M | $68.43M | $-19.80M | $-16.92M | $-10.98M | $-24.33M | $-9.66M | $-10.07M |
| Low Forecast | $-8.24M | $-7.86M | $-7.36M | $-7.16M | $-8.28M | $-7.93M | $-7.57M | $-7.23M | $-7.50M | $-8.19M | $-8.26M | $-44.74M | $-8.01M | $-7.81M | $-9.03M | $-40.68M | $-7.52M | $-8.20M | $-14.61M | $-36.98M | $-14.74M | $-13.51M | $-20.40M | $45.62M | $-19.80M | $-16.92M | $-10.98M | $-36.50M | $-9.66M | $-10.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 20.30% | 8.24% | -1.46% | 0.26% | 5.49% | 11.97% | 4.84% | 1.50% | 2.90% | -4.05% | -0.69% | 1.00% | -3.60% | -2.78% | -6.15% | 1.00% | 8.38% | 3.04% |
4 analysts predict OPK's average Quarter EBITDA for Sep 23 to be $-7.81M, with a high of $-7.81M and a low of $-7.81M. This is -159.19% lower than OPKO Health's previous annual EBITDA (Jun 23) of $13.20M.
OPKO Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-66.52M | $-84.47M | $-19.64M | $-18.20M | $-85.20M | $-86.05M | $-101.38M | $-55.38M | $-73.31M | $28.74M | $-16.19M | $31.08M | $32.30M | $23.72M | $33.70M | $-59.13M | $-112.35M | $-62.01M |
| Avg Forecast | $-34.86M | $-41.83M | $-41.83M | $-48.80M | $-47.06M | $-50.55M | $-50.55M | $-54.03M | $-45.32M | $-65.07M | $-66.24M | $-44.72M | $-69.72M | $-69.72M | $-49.97M | $-40.65M | $-77.86M | $-58.57M | $5.58M | $-36.96M | $-13.94M | $-6.97M | $12.55M | $31.08M | $29.28M | $30.68M | $-46.02M | $-59.13M | $-61.01M | $-62.75M |
| High Forecast | $-34.86M | $-41.83M | $-41.83M | $-48.80M | $-47.06M | $-50.55M | $-50.55M | $-54.03M | $-45.32M | $-45.55M | $-66.24M | $-35.77M | $-61.97M | $-69.72M | $-49.97M | $-32.52M | $-77.86M | $-58.57M | $5.58M | $-29.56M | $-13.94M | $-6.97M | $12.55M | $37.29M | $29.28M | $30.68M | $-46.02M | $-47.31M | $-61.01M | $-62.75M |
| Low Forecast | $-34.86M | $-41.83M | $-41.83M | $-48.80M | $-47.06M | $-50.55M | $-50.55M | $-54.03M | $-45.32M | $-71.58M | $-66.24M | $-53.66M | $-77.47M | $-69.72M | $-49.97M | $-48.78M | $-77.86M | $-58.57M | $5.58M | $-44.35M | $-13.94M | $-6.97M | $12.55M | $24.86M | $29.28M | $30.68M | $-46.02M | $-70.96M | $-61.01M | $-62.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.21% | 0.39% | 0.45% | 1.09% | 1.47% | -18.18% | 1.50% | 5.26% | -4.12% | -1.29% | 1.00% | 1.10% | 0.77% | -0.73% | 1.00% | 1.84% | 0.99% |
OPKO Health's average Quarter net income forecast for Dec 21 is $-13.94M, with a range of $-13.94M to $-13.94M. OPK's average Quarter net income forecast represents a -148.52% decrease compared to the company's last Quarter net income of $28.74M (Sep 21).
OPKO Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $72.77M | $72.24M | $79.79M | $75.70M | $74.00M | $79.67M | $101.46M | $117.54M | $138.21M | $105.12M | $113.24M | $112.29M | $101.82M | $99.90M | $77.72M | $76.13M | $79.13M | $80.54M |
| Avg Forecast | $59.45M | $56.72M | $53.11M | $51.61M | $59.69M | $57.19M | $54.60M | $52.15M | $54.10M | $58.52M | $59.54M | $94.81M | $57.23M | $56.34M | $65.11M | $86.19M | $54.22M | $59.16M | $105.37M | $78.36M | $106.32M | $97.44M | $147.11M | $112.29M | $142.84M | $122.07M | $79.17M | $76.13M | $69.65M | $72.66M |
| High Forecast | $59.45M | $56.72M | $53.11M | $51.61M | $59.69M | $57.19M | $54.60M | $52.15M | $54.10M | $59.09M | $59.54M | $113.78M | $57.76M | $56.34M | $65.11M | $103.43M | $54.22M | $59.16M | $105.37M | $94.03M | $106.32M | $97.44M | $147.11M | $134.74M | $142.84M | $122.07M | $79.17M | $91.36M | $69.65M | $72.66M |
| Low Forecast | $59.45M | $56.72M | $53.11M | $51.61M | $59.69M | $57.19M | $54.60M | $52.15M | $54.10M | $58.06M | $59.54M | $75.85M | $56.70M | $56.34M | $65.11M | $68.96M | $54.22M | $59.16M | $105.37M | $62.69M | $106.32M | $97.44M | $147.11M | $89.83M | $142.84M | $122.07M | $79.17M | $60.91M | $69.65M | $72.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.27% | 1.28% | 1.23% | 0.88% | 1.36% | 1.35% | 0.96% | 1.50% | 1.30% | 1.08% | 0.77% | 1.00% | 0.71% | 0.82% | 0.98% | 1.00% | 1.14% | 1.11% |
OPKO Health's average Quarter SG&A projection for Mar 24 is $94.81M, based on 4 Wall Street analysts, with a range of $75.85M to $113.78M. The forecast indicates a 30.30% rise compared to OPK last annual SG&A of $72.77M (Dec 23).
OPKO Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-8.85 | $-0.11 | $-0.03 | $-0.02 | $-0.11 | $-0.11 | $-0.14 | $-0.08 | $-0.11 | $0.04 | $-0.03 | $0.05 | $0.05 | $0.04 | $0.05 | $-0.09 | $-0.18 | $-0.11 |
| Avg Forecast | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.08 | $-0.07 | $-0.09 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.07 | $-0.08 | $-0.11 | $-0.08 | $0.01 | $-0.06 | $-0.02 | $-0.01 | $0.02 | $0.05 | $0.04 | $0.04 | $-0.07 | $-0.09 | $-0.09 | $-0.09 |
| High Forecast | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.08 | $-0.07 | $-0.07 | $-0.10 | $-0.10 | $-0.09 | $-0.10 | $-0.07 | $-0.08 | $-0.11 | $-0.08 | $0.01 | $-0.06 | $-0.02 | $-0.01 | $0.02 | $0.05 | $0.04 | $0.04 | $-0.07 | $-0.09 | $-0.09 | $-0.09 |
| Low Forecast | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | $-0.08 | $-0.07 | $-0.10 | $-0.10 | $-0.10 | $-0.11 | $-0.10 | $-0.07 | $-0.08 | $-0.11 | $-0.08 | $0.01 | $-0.06 | $-0.02 | $-0.01 | $0.02 | $0.05 | $0.04 | $0.04 | $-0.07 | $-0.09 | $-0.09 | $-0.09 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 88.50% | 1.10% | 0.36% | 0.32% | 0.99% | 1.31% | -17.50% | 1.50% | 5.50% | -4.00% | -1.67% | 1.04% | 1.19% | 0.91% | -0.76% | 1.03% | 2.06% | 1.22% |
According to 4 Wall Street analysts, OPKO Health's projected average Quarter EPS for Dec 21 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -150.00% decrease compared to OPK previous annual EPS of $0.04 (Sep 21).
OPKO Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DMTK | DermTech | $0.09 | $15.00 | 16566.67% | Buy |
| TTOO | T2 Biosystems | $1.36 | $5.00 | 267.65% | Hold |
| GH | Guardant Health | $20.68 | $57.27 | 176.93% | Buy |
| OPK | OPKO Health | $1.46 | $3.50 | 139.73% | Buy |
| FLGT | Fulgent Genetics | $19.66 | $45.00 | 128.89% | Buy |
| BDSX | Biodesix | $1.63 | $3.00 | 84.05% | Buy |
| ILMN | Illumina | $143.52 | $199.67 | 39.12% | Buy |
| CDNA | CareDx | $24.48 | $31.00 | 26.63% | Buy |
| CSTL | Castle Biosciences | $33.06 | $40.50 | 22.50% | Buy |
| A | Agilent | $137.42 | $152.64 | 11.08% | Buy |
| IDXX | IDEXX Laboratories | $460.01 | $479.75 | 4.29% | Buy |
| NTRA | Natera | $122.35 | $114.38 | -6.51% | Buy |
| TWST | Twist Bioscience | $45.52 | $42.40 | -6.85% | Buy |
| ME | 23andMe | $4.91 | $3.71 | -24.44% | Buy |
OPK Forecast FAQ
Is OPKO Health a good buy?
Yes, according to 10 Wall Street analysts, OPKO Health (OPK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 50.00% of OPK's total ratings.
What is OPK's price target?
OPKO Health (OPK) average price target is $3.5 with a range of $3 to $4, implying a 138.10% from its last price of $1.47. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will OPKO Health stock go up soon?
According to Wall Street analysts' prediction for OPK stock, the company can go up by 138.10% (from the last price of $1.47 to the average price target of $3.5), up by 172.11% based on the highest stock price target, and up by 104.08% based on the lowest stock price target.
Can OPKO Health stock reach $2?
OPK's average twelve months analyst stock price target of $3.5 supports the claim that OPKO Health can reach $2 in the near future.
What are OPKO Health's analysts' financial forecasts?
OPKO Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $693.74M (high $693.74M, low $693.74M), average EBITDA is $-31.007M (high $-31.007M, low $-31.007M), average net income is $-202M (high $-202M, low $-202M), average SG&A $223.63M (high $223.63M, low $223.63M), and average EPS is $-0.29 (high $-0.29, low $-0.29). OPK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $685.22M (high $685.22M, low $685.22M), average EBITDA is $-30.627M (high $-30.627M, low $-30.627M), average net income is $-167M (high $-167M, low $-167M), average SG&A $220.89M (high $220.89M, low $220.89M), and average EPS is $-0.24 (high $-0.24, low $-0.24).
Did the OPK's actual financial results beat the analysts' financial forecasts?
Based on OPKO Health's last annual report (Dec 2023), the company's revenue was $863.5M, beating the average analysts forecast of $747.63M by 15.50%. Apple's EBITDA was $-157M, beating the average prediction of $-58.671M by 167.63%. The company's net income was $-189M, missing the average estimation of $-230M by -17.91%. Apple's SG&A was $300.56M, beating the average forecast of $264.87M by 13.47%. Lastly, the company's EPS was $-25.12, beating the average prediction of $-0.348 by 7111.47%. In terms of the last quarterly report (Dec 2023), OPKO Health's revenue was $181.88M, beating the average analysts' forecast of $177.53M by 2.45%. The company's EBITDA was $-161M, beating the average prediction of $-7.935M by 1929.80%. OPKO Health's net income was $-66.523M, missing the average estimation of $-69.721M by -4.59%. The company's SG&A was $72.76M, beating the average forecast of $57.23M by 27.15%. Lastly, the company's EPS was $-8.85, beating the average prediction of $-0.1 by 8750.00%